Diakonos Technologies

The Diakonos Science is centered on the body's ability to fight cancer naturally. Through novel approaches, the Diakonos treatments each activate the immune system to specifically target the tumor cells and have the potential to generate immunological memory to inhibit relapse.

With all discoveries emanating from the Texas Medical Center, these protocols have been thoroughly tested and demonstrated success in the clinical setting. Human clinical trials are underway through both the Diakonos Team and partners distributed throughout the world.

Patented Double Loading of Dendritic Cells
Results in a Powerful Immune Response

After Dendritic Cell education and co-culture with T-cells, the powerful CD8+ T cells release a compound called Interferon Gamma, which further stimulates a TH1 response capable of ultimately destroying mutated, cancerous cells. Therefore, the "anti-tumor potential" of each Dendritic Cell treatment can in part be represented by the amount of Interferon Gamma subsequently released by the responding T cells.

In this set of experiments, various approaches to Dendritic Cell Loading and their subsequent anti-tumor potential were measured. The Diakonos dual MHC Class 1 & 2 simultaneous activation creates unmatched CD8+ T cell stimulation and has the strongest anti-tumor potential.

The higher concentration of Interferon Gamma correlates to more "red spots" in the ELISpot Wells. As can be seen above, the anti-tumor activity of Diakonos' treatment is significantly stronger than the existing Dendritic Cell Treatments.

Dendritic Cell Vaccine Validation

Since 2006, the Diakonos Team has been focused on methodically confirming the revolutionary discovery of its Dendritic Cell Cancer Treatment.

Dendritic Cell Mechanistic Understanding
From the early 2000's when the foundational, revolutionary Dendritic Cell mechanism was discovered, the Diakonos team has been efficiently successful in continuing to study and understand the true nature of Dendritic Cell biology unlike ever before. This research was conducted and published at MD Anderson Cancer Center and Baylor College of Medicine.

Decker et al, 2006; Decker et al, 2008; Decker et al, 2009;  Halpert et al, 2020

Unique TH1 Response Confirmation
With a clear understanding of the Dendritic Cell phenomenon, Diakonos has been able to further identify unique effector molecules and cells that result from this specialized Dendritic Cell education, mediators that in and of themselves possess specialized attributes all focused on the promulgation of an optimal TH1 immune response. This research was conducted and published at Baylor College of Medicine.

Publications: Halpert and Konduri et al, 2016; Liang et al, 2018; Konduri et al, 2021

Clinical Demonstration
On the other side of the coin from scientific understanding is clinical applicability, something that Diakonos has repeatedly delivered in a range of cancers, from animals to people, and in real world situations. This research was conducted and published at Baylor College of Medicine.

Publications: Konduri et al, 2016; Konduri and Halpert et al, 2019; unpublished data

Intratumoral Injection

"Multifactorial Immune Modulation"

Intratumoral delivery of immunotherapy agents hold promise in leveraging the power of immunotherapy through immediate action and minimizing off-target side effects. The direct injection of immune stimulating agents into the tumor primes the local tumor-specific immunity to generate a systemic, durable clinical response.

Diakonos has developed a patented combination of immunotherapy agents designed to be injected intratumorally, referred to as "Multifactorial Immune Modulation". This combination has demonstrated efficacy in tumor lysis, increasing tumor antigen expression, and eliminating immunosuppression.

In vivo experiments have demonstrated success in completely eliminating solid tumors and generating subsequent immunological memory to prevent relapse. Diakonos plans to target clinical trials at the beginning of 2023.

Solid Tumor CAR T cell Therapy

Although therapy with CAR-T cells has produced promising responses in certain subsets of B cell leukemia or lymphoma, many challenges restrict the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Prior Solid Tumor CAR-T therapies have been ineffective previously due to their low concentrations of tissue-specific T cells that can target solid tumors effectively.

In creating a unique TH1 immune response with our patented Dendritic Cell protocol, the Diakonos team discovered the robust and durable effectiveness of a unique population of responding CD8 T cells.  

Studies have validated that these CD8 T cells have improved homing, lytic, and memory capabilities. Diakonos patented process increases the CD8 T cell concentration initially and improves their stability during expansion to take advantage of these biological advantages.

SCID mice were utilized in a difficult to treat pancreatic cancer model, and subsequently treated with adoptively primed standard T cells or Diakonos T cells.